Hood River Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Hood River Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-623,421	Closed	-$20.9M	–	189
2026 Q1	$20.9M	Buy	623,421 +5,416	+0.9%	+$212K	0.21%	111
2025 Q4	$28.6M	Buy	618,005 +4,611	+0.8%	+$253K	0.31%	92
2025 Q3	$41.5M	Buy	+613,394	New	+$45.5M	0.49%	70

Hood River Capital Management's SLNO Position: Q2 2026 in Review

Hood River Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 623,421 shares — an estimated $20.9M sold.

Hood River Capital Management first reported a position in SLNO in Q3 2025 and held it in 3 quarters. The position peaked at $41.5M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Hood River Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Hood River Capital Management sold 623,421 Soleno Therapeutics shares in Q2 2026, an estimated $20.9M.
Hood River Capital Management first reported a position in Soleno Therapeutics in Q3 2025 and held it in 3 quarters.
Hood River Capital Management's Soleno Therapeutics position peaked at $41.5M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Hood River Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.